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 Abstract: Background: Melatonin is a natural body product that has shown potent antioxidant prop-
erty against various toxic agents. For more than two decades, the abilities of melatonin as a potent ra-
dioprotector against toxic effects of ionizing radiation (IR) have been proved. However, in the recent 
years, several studies have been conducted to illustrate how melatonin protects normal cells against 
IR. Studies proposed that melatonin is able to directly neutralize free radicals produced by IR, leading 
to the production of some low toxic products. Moreover, melatonin affects several signaling path-
ways, such as inflammatory responses, antioxidant defense, DNA repair response enzymes, pro-
oxidant enzymes etc. Animal studies have confirmed that melatonin is able to alleviate radiation-
induced cell death via inhibiting pro-apoptosis and upregulation of anti-apoptosis genes. These prop-
erties are very interesting for clinical radiotherapy applications, as well as mitigation of radiation inju-
ry in a possible radiation disaster. An interesting property of melatonin is mitochondrial ROS target-
ing that has been proposed as a strategy for mitigating effects in radiosensitive organs, such as bone 
marrow, gastrointestinal system and lungs. However, there is a need to prove the mitigatory effects of 
melatonin in experimental studies. 
Conclusion: In this review, we aim to clarify the molecular mechanisms of radioprotective effects of 
melatonin, as well as possible applications as a radiation countermeasure in accidental exposure or 
nuclear/radiological disasters. 
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1. INTRODUCTION 
Treatment with radiation modalities is one of the most 
common methods for tumor control [1]. This can be done by  
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high energy x-rays photons, electrons, heavy particle irradia-
tion, or by injection of radioactive drugs in radiopharmacy 
[2-4]. The most important aim in these modalities is delivery 
of the highest possible radiation dose to tumor cells with 
lower side effects. However, because surrounding normal 
tissues are exposed to high doses of radiation, appearance of 
acute and late side effects is usual [5, 6]. Although, techno-
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logical improvements have enhanced targeted radiotherapy, 
possible toxicity in normal tissues still remains a concern [7-
9]. Administration of radioprotectors is one of the strategies 
for increasing the therapeutic ratio by reducing normal tissue 
injury [10]. However, there are some concerns related to 
possible protection of tumor cells to radiotherapy [11, 12]. 
Moreover, results from in-vivo studies have shown that a 
specific radioprotector may not be able to protect various 
organs because of limited diffusion in different organs, and 
also different responses of normal tissues to ionizing radia-
tion [13, 14]. The toxicity of administered radioprotector is 
another concern. Acute side effects of these radioprotectors 
may cause severe toxicity in patients [15]. 
Based on the above mentioned issues, an appropriate ra-
dioprotector should have low toxicity, applicable to different 
organs, and also protects normal tissue cells without any 
protective effect on tumor cells. Amifostine is the first FDA 
approved drug for radioprotection against radiation-induced 
xerostomia in head and neck cancer patients [16]. However, 
amifostine may cause severe reactions in treating patients 
[17]. In addition, amifostine only has protective effect for 
some organs [18, 19]. Hence, in recent years, a large number 
of studies have been conducted to identify other radioprotec-
tive agents with low toxicity and more efficiency [12]. 
Among various types of proposed agents, results from stud-
ies have suggested that natural and herbal radioprotectors 
have potentials for better radioprotection with low toxicity 
[20]. However, there is a crucial need to evaluate the possi-
ble effects on different types of tumor cells. 
2. PROPERTIES FOR APPROPRIATE RADIATION 
COUNTERMEASURE 
The first consequence of radiation interaction with vital 
cells is DNA damage and ROS production. Normal cells have 
different capacities for repair of DNA damage and scavenging 
of free radicals. Following exposure to a high dose of ionizing 
radiation, cell death may occur as a result of overwhelming 
DNA damage and poor repair mechanisms. In addition to di-
rect ROS production by ionizing radiation, endogenous free 
radicals, such as ROS and nitric oxide (NO) play a key role in 
the appearance of radiation-induced consequences. Cell death 
and oxidative DNA damage are mostly responsible for chronic 
oxidative injury following exposure. Emerging evidences have 
shown that oxidized DNA and danger alarms, which are se-
creted from dying cells, upregulate several signaling pathways 
involved in reduction/oxidation reactions and chronic inflam-
mation. Toll like receptors (TLRs) which include TLR2, TLR4, 
TLR5 and TLR9 are involved in these processes. Inhibition of 
TLRs such as TLR5 have shown more efficiency for radiopro-
tection and mitigation compared to amifostine. TLRs are the 
main stimulators of free radical production by other pro-
oxidant enzymes and mitochondria. In addition to TLRs, sup-
pression of other ROS producing enzymes, mitochondria and 
inflammatory mediators have been proposed for protection and 
mitigation of radiation injury. Although, targeting mitochon-
dria has shown more promising results. 
3. MELATONIN 
Melatonin is the main product of the pineal gland, which 
is synthesized from amino acid tryptophan and regulates 
circadian rhythm [21]. It is normally synthesized and secret-
ed during darkness in the pineal gland [22]. It can also be 
produced and secreted by other human body cells in the reti-
na, skin, lymphocytes, gastrointestinal tract and some other 
tissues [23]. It is involved in several signaling between the 
nervous and immune system cells [24]. The main effects of 
melatonin can be applied via two receptors, including MT1 
and MT2 [25]. Furthermore, melatonin acts by binding to 
cytoplasmic and nuclear proteins like calmodulin and 
RZR/ROR [26]. Due to its high lipophilic property, melato-
nin can penetrate different cells and tissues, and affect gene 
regulation [27]. Melatonin has interesting properties which 
make it potent protector against various oxidants and in-
flammatory agents. It has shown ability to enhance DNA 
repair caused by various agents, such as ultraviolet radiation, 
ionizing radiation, chemotherapy agents, and some other 
mutagens [28-31]. This property of melatonin has a potent 
relationship with direct interaction with enzymes involved in 
DNA repair. For example, melatonin via direct phosphoryla-
tion of Ser-15 in p53 prevents cell proliferation, providing 
more time for repair of damaged DNA. Hence, accumulated 
DNA damage is avoided as well as a reduction in cell death 
or probability of genomic instability [32]. 
Melatonin has shown potent anti-inflammatory properties 
through effects on several mediators. For example, melatonin 
is a potent inhibitor of TLRs that are involved in the promo-
tion of inflammation. Suppression of TLR4 by melatonin can 
attenuate upregulation of caspase 3 (as an apoptosis cell 
death marker), activates survivor activating factor enhance-
ment, and ameliorates increased inflammatory cytokines and 
mediators [33-35]. Suppression of other inflammatory medi-
ators have been observed following exogenous administra-
tion of melatonin [36-38]. Also, through suppression of pro-
oxidant enzymes and mitochondria, it protects normal cells 
against endogenous ROS and NO following exposure to tox-
ic agents [39-41]. As a result of these properties, melatonin 
is a potential agent for radiation protection[42]. 
4. MELATONIN AND IONIZING RADIATION 
For many years, melatonin has been well known to pro-
tect normal cells against radiation. Earlier studies showed a 
reduction in radiation-induced chromosome aberrations in 
cultured cells following melatonin treatment. Further in vitro 
and in vivo studies have confirmed its potent radioprotective 
effect [43]. A systematic review by Zenter et al. showed that 
melatonin can be proposed for protection against oxidative 
injury, inflammation and death caused by ionizing radiation 
[44]. Emerging evidences have shown that melatonin reduc-
es radiation-induced chromosome aberrations and cell death. 
Treatment of human monocytes with 2 mM melatonin for 24 
hours caused a 60% reduction in DNA damage [45, 46]. 
Similarly, oral administration of 300 mg melatonin to hu-
mans followed by 1.5 Gy gamma rays irradiation of their 
lymphocytes also produced a 60% reduction in DNA damage 
[47, 48]. Its protective effect was also observed for heavy 
radiation particles as 40% [45]. Similar results were shown 
for different cells and tissues in in vitro and in vivo studies 
[49-55]. 
In the following sections, we explained the molecular 
mechanisms for protective effect of melatonin against radia-
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tion toxicity. We focused on possible mechanisms that may 
be proposed for both radiation protection and mitigation. 
These mechanisms may propose melatonin as a potent radia-
tion countermeasure. In addition to possible radioprotective 
effect of melatonin, some recent studies have shown synergic 
therapeutic effect of melatonin on cancer cells when admin-
istered with ionizing radiation [56, 57]. Recently, melatonin 
has been proposed as an adjuvant for breast cancer radiother-
apy for both radioprotective and radiosensitization aims [58]. 
However, studies evaluating radiosensitization by melatonin 
are limited to some in vitro studies because these studies 
only dealt with the clinical applications of melatonin as a 
potential adjuvant. 
5. SCAVENGING OF IR-INDUCED FREE RADICALS 
BY MELATONIN 
The primary function of melatonin in human or plant is 
related to its antioxidant effect. Several evidences have re-
vealed that melatonin acts as a potent radical scavenger [21, 
59, 60]. One of the most reactive and toxic free radicals that 
is produced following exposure to IR is the hydroxyl radical 
(OH), which is produced after a cascade of reactions [61]. 
Superoxide anion (O2-) is another type of free radical that is 
neutralized by superoxide dismutase (SOD) [62]. H2O2 is a 
product of the interaction of IR with water molecules with 
higher half-life. This type of free radical can be neutralized 
by catalase (CAT) or glutathione peroxidase (Gpx) [63]. In 
addition to the direct products of IR interaction with water 
molecules in cells, nitric oxide (NO) which is a product of 
inflammatory cells plays a key role in IR-induced oxidative 
injury [64]. NO is involved in various immunological and 
physiological functions, and it may be converted to the per-
oxynitrite anion (ONOO-) in mitochondria [65, 66]. This is 
highly toxic and can cause mutation in DNA via direct inter-
action or suppression of DNA damage responses [67, 68]. 
Melatonin has the ability to neutralize both ROS and NO 
directly or indirectly. In direct action of melatonin, it reacts 
with free radicals leading to the production of less/non-toxic 
agents [69, 70]. In an indirect action, it stimulates antioxi-
dant enzymes and suppresses pro-oxidant enzymes [71, 72]. 
Taysi et al. showed that treatment with low doses of melato-
nin, such as 5 mg kg–1 and 10 mg kg–1 before whole body 
irradiation of rats with 5 Gy upregulates serum level of both 
GPx and SOD, and reduces oxidative injury in a dose de-
pendent manner [73]. Similar results have been shown by 
Erol et al. They treated rats with 100 mg/kg per day of mela-
tonin or alpha-tocopherol before brain irradiation with 72 Gy 
in 2 fractions. Their results indicated that melatonin is able 
to ameliorate oxidative injury and pathological changes such 
as neuronal degeneration, edema, and necrosis, while alpha-
tocopherol was less effective in reducing these damages [74]. 
Similar results have also been observed for various organs in 
some other studies [75-82]. By contrast to other classic anti-
oxidants like ascorbic acid, which promotes ROS production 
by redox system, melatonin interacts with ROS and NO as-
sociated with redox system inhibition [83, 84]. The activa-
tion of nuclear factor erythroid 2-related factor 2 (nrf2) plays 
a key role in indirect activity of melatonin. Guo et al. 
showed that suppression of oxidative stress by melatonin is 
associated with upregulation of nrf2 and heme oxygenase-1 
(HO-1) [85]. This property of melatonin has been confirmed 
by other authors in different studies [86-89]. 
6. MELATONIN MODULATES REDOX ACTIVITY 
FOLLOWING EXPOSURE TO IR 
A large number of studies have confirmed that chronic 
free radical production by irradiated or adjacent non-
irradiated cells plays a key role in radiation toxicity [90, 91]. 
Studies have proposed that ROS/NO producing enzymes 
such as mitochondria, membrane, endoplasmic reticulum and 
lysosomes in cells, are involved in this process [92]. Modu-
lation of free radical production in these enzymes and orga-
nelles have been proposed for amelioration of radiation tox-
icity [93]. The most important enzymes in this process in-
cludes nicotinamide adenine dinucleotide phosphate oxidase 
(NADPH oxidase), cyclooxygenase-2 (COX-2), inducible 
nitric oxide synthase (iNOS) and lipoxygenases (LOXs) 
[90]. 
6.1. Melatonin and ROS/NO Producing Enzymes after 
Exposure to Radiation 
Depending on the irradiated tissues, ROS/NO production 
may continue for a long time after exposure. Moreover, 
sources of free radicals in cells vary for different cell types 
[94]. For example, in mice, production of ROS in the bone 
marrow cells has been detected 8 weeks after exposure [95]. 
The main sources of ROS in bone marrow and fibroblast 
cells after exposure to radiation are NADPH oxidase (NOX) 
4 and NOX5 [96]. NOX2 as well as other subfamily of 
NADPH oxidase are involved in radiation-induced oxidative 
injury in the brain, microvascular and gastrointestinal system 
[97-101]. Furthermore, a relationship between NOX2 and 
cell death has been detected for human liver cancer cell, lung 
cancer cells and cervical cancer cells [102]. The roles of oth-
er enzymes such as COX-2 and iNOS have been proposed 
for radiation induced chronic oxidative stress in the bone 
marrow, lung, heart and joints [103-107]. 
Melatonin has shown ability to attenuate expression of 
redox genes and subsequent free radical production [108]. 
Melatonin can decrease the production of superoxide anion 
by NADPH oxidase in microglia. This is associated with 
inhibition of PI3K/Akt signaling pathway and suppression of 
the translocation of NADPH oxidase subunits to the mem-
brane [109]. Moreover, melatonin via suppression of protein 
kinase C (PKC) attenuates upregulation of NADPH oxidase 
[110]. Li et al. showed that treatment of mice with 5 mg/kg 
melatonin reduces expression of NOX4 in bone marrow stem 
cells, ameliorates free radical toxicity and increases survival 
after total body irradiation with 7.2 Gy. They showed that 
treatment with melatonin attenuates micronuclei formation in 
different subtypes of bone marrow cells including hemato-
poietic stem cells and progenitor cells as well as bone mar-
row mononucleated cells [111]. In addition to NADPH oxi-
dase, melatonin has shown ability to ameliorate upregulation 
of COX-2 and iNOS enzymes as well as oxidative injury 
after irradiation of rat’s lung. Results of two studies revealed 
that treatment with 100 mg/kg melatonin before local irradia-
tion of rats pelvis reduces oxidative injury and attenuates 
upregulation of COX-2 and iNOS [112, 113]. Moreover, 
melatonin has shown that through suppression of prostaglan-
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dins, ameliorates radiation myelopathy in rat’s cervical spi-
nal cord [114-116]. 
6.2. Melatonin and Mitochondrial Activity After Expo-
sure to Radiation 
Mitochondria within cells generate ATP as the energy 
source. The synthetize of ATP is associated with the oxida-
tive phosphorylation in the inner membrane of mitochondria. 
This procedure is associated with superoxide production. 
Under normal conditions, mitochondrial antioxidant en-
zymes such as superoxide dismutase and catalase are able to 
neutralize this amount of superoxide. However, damage to 
the mitochondrial DNA (mtDNA) may disrupt normal func-
tions of mitochondria, leading to the overproduction of su-
peroxide. As the mtDNA is highly vulnerable to free radi-
cals, oxidative stress conditions may stimulate chronic su-
peroxide production via damage to mtDNA. Overproduction 
of ROS may overwhelm antioxidant defense, causing more 
injuries to other organelles and DNA. Ortiz et al. confirmed 
that damage to mitochondria after exposure to radiation is as 
a result of overproduction of free radicals [117]. 
Several studies have shown that the mitochondria are one 
of the main sources of free radicals following exposure to IR. 
Leach et al. evaluated the effect of ionizing radiation on mi-
tochondria induced ROS and NO in different types of cells 
such as A431 squamous carcinoma, breast carcinoma, 
DU145 etc. Their results showed that after exposure to radia-
tion (1-10Gy), the percentage of ROS/NO producing cells 
increased in a dose dependent manner. Further analyses 
showed that suppression of mitochondria activity is associat-
ed with inhibition of ROS/NO production. Furthermore, they 
showed that activation of MAPKs and calcium ions are nec-
essary for mitochondria induced free radical production 
[118]. 
In addition to free radical production, the mitochondria 
have a pivotal role in radiation-induced apoptosis. This is 
very crucial for cells with high expression of pro-apoptosis 
genes such as p53 and Bax. It has been demonstrated that 
binding of p53 to mitochondria is an important pathway for 
stimulating radiation-induced apoptosis [119]. Melatonin 
(0.001M concentration) has been shown to attenuate the up-
regulation of pro-apoptosis genes such as casp-9, casp-3 and 
casp-7 in human HaCaT keratinocytes during stress condi-
tions. Moreover, melatonin treatment could reverse mito-
chondrial potential changes following UV irradiation [120]. 
Mohseni et al. showed that treatment of rats with 10 or 100 
mg/kg melatonin before exposure to gamma radiation atten-
uates apoptosis via upregulation of bcl-2 and downregulation 
of Bax gene in peripheral circulating lymphocytes [121]. 
7. INHIBITION OF DNA DAMAGE RESPONSES AF-
TER EXPOSURE TO IR; STIMULATORY EFFECT 
OF MELATONIN 
DNA damage response is one of the first cell response to 
genotoxic effects of IR. Evidences have shown that IR via 
stimulation of NO production from macrophages or lympho-
cyte T limits regulation of some DNA repair genes such as 8-
oxoguanine glycosylase (Ogg1) [94]. Chronic NO produc-
tion, which is one of the consequences of redox system acti-
vation by IR may play a key role in genomic instability and 
carcinogenesis [122]. Increased NO production has been 
confirmed in some tumor cells such as in breast cancer [123]. 
NO can be produced by some types of nitric oxide synthases, 
including neuronal NOS (nNOS), endothelial NOS (eNOS) 
and iNOS [124]. However, studies have shown that iNOS is 
primarily responsible for NO production following exposure 
to IR [125, 126]. After exposure to IR, NO can inhibit Ogg1 
activity via nitrosylation of the zinc-finger motif of this en-
zyme [127, 128]. Due to the involvement of ogg1 in base 
excision repair (BER) pathway via excision of oxidized gua-
nine (8-oxoguanine), suppression of its activity leads to ac-
cumulation of unrepaired damaged DNA. Mutation in ogg1 
and other BER pathway genes has been reported in the lung, 
head and neck and kidney cancers [129-132]. 
Several evidences have reported that melatonin is a po-
tent stimulator of DNA damage responses [133, 134]. Sli-
winski et al. showed that treatment of human lymphocytes 
with melatonin increases the kinetics of DNA repair after 
exposure to H2O2. In addition, they revealed that melatonin 
does not increase the expression of BER pathway genes [29]. 
In contrast to this study, Rezapoor et al. showed that treat-
ment of rats with 100 mg/kg of melatonin before exposure to 
3 or 8 Gy upregulates the expression of BER pathway genes 
such as Ogg1, Apex1, and Xrcc1. However, irradiation with-
out melatonin treatment inhibited BER pathway genes po-
tently. They showed that the inhibitory effect of IR on this 
pathway can be seen 8 h after exposure. However, the most 
stimulatory effect of melatonin was revealed 24 h after expo-
sure [135]. These results were confirmed by another study by 
Karbownik and colleagues. They revealed that administering 
melatonin (50mg/kg) to rats before irradiation with 8 Gy 
attenuates 8-hydroxy-2'-deoxyguanosine formation in liver 
[136]. Another study showed that melatonin reduces both 
iNOS level and 8-hydroxy-2'-deoxyguanosine formation in 
the lung tissue of rat [112]. Upregulation of other DNA re-
pair pathways including non-homologous end joining 
(NHEJ) after irradiation with 3 and 8 Gy, as well as treat-
ment with 100 mg/kg of melatonin has been observed in an-
other study. [137]. 
8. ANTI-INFLAMMATORY AND ANTI-FIBROSIS 
PROPERTIES OF MELATONIN IN RADIOTHERAPY 
Inflammation and fibrosis are two degenerative phenom-
ena which are responsible for several side effects after radio-
therapy. Inflammation can lead to various appearances in 
different organs. Pneumonitis in the lung, dermatitis, arthri-
tis, myelopathy, gastritis, enteritis as well as autoimmune 
diseases are some examples [94, 138]. In addition to these 
side effects, a massive data has shown a relation between 
inflammation and second primary cancers following radio-
therapy [139]. Although, inflammation in some organs such 
as gastrointestinal system and skin may cause chronic pain 
and bleeding, pneumonitis and myelopathy are more danger-
ous and may threaten the life of irradiated people. Fibrosis 
has a potent link to inflammation in irradiated organs. Fibro-
sis is a late effect of radiotherapy that affects the quality of 
life of radiotherapy patients for many years. In addition, fi-
brosis in the lung or heart may threaten the life of patients. 
Melatonin has shown ability to ameliorate inflammatory 
mediators, cytokines and transcription factors in different 
organs [83]. As oxidative damage is a potent stimulator of 
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inflammation, it has been proposed that melatonin via its 
antioxidative and immunoregulatory properties, prevents 
inflammation after exposure to IR [140]. In addition to the 
antioxidant roles of melatonin that has been described earli-
er, melatonin can inhibit inflammation in different levels 
[140]. 
Inflammation can be initiated after DNA damage and cell 
death, leading to the release of some danger signals from 
dead cells to macrophages and lymphocytes. Necrosis and 
oxidative DNA damage through bind to TLRs such as TLR4 
and TLR5 upregulate expression of transcription factors like 
NF-κB, signal transducer and activator of transcription 
(STATs) [141, 142]. This is associated with increase in the 
level of inflammatory mediators such as COX-2 and iNOS. 
Upregulation of transcription factors and inflammatory me-
diators lead to the secretion of inflammatory cytokines such 
as IL-1, IL-6, IL-8, IL-33, TNF-α [143]. Interaction of mac-
rophages with apoptotic bodies causes secretion of anti-
inflammatory cytokines such as IL-10 and TGF-β [144]. 
Melatonin via boosting DNA repair responses and reducing 
oxidative damage prevents the release of danger alarms. In 
addition, melatonin can reduce the expression of TLR4 that 
is activated by danger alarms [145]. Suppression of NF-κB 
by melatonin can be obtained via upregulation of its antag-
onist, IκB. Mohan et al. showed that direct inhibition of 
NF-κB is involved in amelioration of radiation injury fol-
lowing treatment of HeLa S3 cells with melatonin [146]. 
Inhibition of NF-κB by melatonin can reduce infiltration of 
inflammatory cells, leading to decreasing inflammatory 
cytokines [147]. 
Several in vitro and in vivo studies have confirmed that 
administration of melatonin prior to IR exposure alleviates 
inflammatory responses and its consequences [148]. Serin et 
al. showed that administration of 100 mg/kg melatonin be-
fore gamma ray irradiation of rat’s lung can reduce alveolar 
edema, macrophages and lymphocyte infiltration [149]. 
Treatment with 50 mg/kg melatonin before irradiation (18 
Gy) of rat’s heart showed that it can potently reduce accumu-
lation of mast cells, macrophages, lymphocytes and also 
ameliorates inflammation and fibrosis 6 months after irradia-
tion [150]. Furthermore, melatonin has shown ability to at-
tenuate pro-inflammatory and pro-fibrosis cytokines in the 
rat’s lung [151]. The use of melatonin gel has shown reduc-
tion in mucositis in rat’s tongue and small intestine. It has 
also shown that inhibition of inflammasome pathway is in-
volved in mucositis suppression by melatonin [117, 152]. 
Dermatitis is another inflammasome involved phenomenon 
that has been shown to be inhibited by melatonin. A double-
blind randomized trial has revealed that melatonin based 
cream inhibits dermatitis in radiotherapy patients with breast 
cancer. They showed that using melatonin cream (twice daily 
during treatment for 2 weeks after the end of radiotherapy 
treatment) reduced grade 1 and 2 up to 90% [153]. Melatonin 
via suppression of prostaglandins production by COX-2 and 
oxidative damage ameliorate radiation myelopathy in rat’s 
spinal cord. This effect has been observed following admin-
istration of 100 mg/kg melatonin before exposure to 22 Gy 
gamma rays [114, 116]. 
9. PROTECTIVE EFFECT OF MELATONIN ON BY-
STANDER/NON-TARGETED CELLS 
The bystander effect can cause free radical production 
and mutation in adjacent non-irradiated cells. A similar phe-
nomenon can be observed in distant non-irradiated organs 
known as non-targeted effect. Studies have proposed that 
these may occur via gap-junction mediated cell-to-cell con-
tact or through some soluble transmissible factors. Some 
studies proposed that redox system activation is responsible 
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Fig. (1). Mechanisms for radioprotection by melatonin. 
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for DNA damage and cell death in non-irradiated cells [90, 
154]. This is associated with increasing inflammatory re-
sponses and attenuation of antioxidant enzymes activity in 
non-irradiated cells/tissues [155-158] (Fig. 1). 
Marozik et al. in an in-vitro study showed that melatonin 
is able to ameliorate micronuclei formation in HPV-G cells 
which were exposed to blood serum of Chernobyl survivors. 
Their results indicated that exposure to an acute ionizing 
radiation can trigger chronic production of clastogenic fac-
tors. Melatonin can neutralize consequences of exposure to 
these clastogenic factors on non-irradiated cells [159]. In 
another in-vivo study, it was shown that melatonin can at-
tenuate overproduction of COX-2 and iNOS enzymes, as 
well as reduction of oxidative damage in non-targeted lung 
tissues following local pelvis irradiation. Moreover, melato-
nin can stimulate activation of antioxidant enzymes such as 
superoxide dismutase and glutathione in non-targeted lung 
tissues [113]. 
CONCLUSION AND FUTURE DIRECTIONS 
Potent radioprotective effect of melatonin, low toxicity 
and good penetration in different cell types are the interest-
ing properties which make it an appropriate candidate for 
both clinical radiotherapy and radiation disaster. Potent anti-
oxidant effects and fast absorption of melatonin in different 
organs help to achieve good radioprotection when adminis-
tered before exposure to IR. In addition, it can through stim-
ulation of DNA repair enzymes facilitate repair in damaged 
cells, leading to lower number of dead cells. This can be 
associated with lower probability of acute reactions in cancer 
patients, as well as long term inflammatory side effects. 
Melatonin has shown ability to reduce oxidative DNA dam-
age and genomic instability in both directly irradiated as well 
as non-irradiated cells/organs, which may reduce the risk of 
second primary cancers. Redox modulatory and anti-
inflammatory properties of melatonin also make it a potential 
agent for mitigation of radiation injury. As earlier men-
tioned, exposure to IR causes upregulation of some redox-
mediated enzymes, leading to amplification of radiation tox-
icity via continuous production of NO and ROS. NADPH 
oxidase enzymes and mitochondria are the most important 
ROS sources after exposing bone marrow and gastrointesti-
nal system cells to IR. In in-vivo studies, melatonin has 
shown downregulation of NADPH oxidase in both bone 
marrow and gastrointestinal system. Furthermore, melatonin 
via upregulation of anti-apoptosis genes such as Bcl-2 and 
suppression of Bax as a pro-apoptosis gene can protect radi-
osensitive cells in these organs. In small intestine, which is 
one of the most critical targets for radiation injury in radio-
logical or nuclear disaster, melatonin has shown that it can 
via suppression of NLRP2/inflammasome pathway alleviate 
the consequences of radiation toxicity. 
As we have mentioned in this review, melatonin protects 
cells against radiation through several mechanisms. It can be 
proposed as a potent radiation countermeasure because of its 
properties such as DNA repair boosting, anti-inflammatory 
and redox modulatory effects. Melatonin, through stimula-
tion of DNA repair responses reduces cell death, improves 
tissue tolerability and also prevents initiation of several sig-
naling pathways involved in chronic inflammation and redox 
reactions. Moreover, melatonin via targeting several inflam-
matory agents alleviates early and late side effects of radio-
therapy such as pneumonitis, fibrosis, dermatitis, mucositis, 
myelopathy etc. The most important targets for melatonin are 
prostaglandins, TLRs, inflammasome, transcription factors 
such as NF-κB, and mitochondria. Targeting of these medi-
ators have been proposed for both radioprotection and mit-
igation of radiation injury. For example; experimental stud-
ies have proved that inhibition of TLRs and mitochondria 
alleviate radiation toxicity in radiosensitive organs. In con-
clusion, it is possible that melatonin via inhibition of redox-
inflammation interactions alleviates chronic ROS/NO pro-
duction, leading to reduction of organ failure, radiation syn-
dromes and risk of carcinogenesis in irradiated and non-
irradiated organs. However, further experimental studies are 
needed to confirm this hypothesis. 
CONSENT FOR PUBLICATION 
Not applicable. 
CONFLICT OF INTEREST 
The authors declare no conflict of interest, financial or 
otherwise. 
ACKNOWLEDGEMENTS 
Declared none. 
REFERENCES 
[1] Reboul, F.L., Radiotherapy and chemotherapy in locally advanced 
non-small cell lung cancer: preclinical and early clinical data. He-
matol. Oncol. Clin. North. Am., 2004, 18. 
[2] Denis-Bacelar, A.M.; Chittenden, S.J.; McCready, V.R.; Divoli, A.; 
Dearnaley, D.P.; O’Sullivan, J.M.; Johnson, B.; Flux, G.D., Bone 
lesion absorbed dose profiles in patients with metastatic prostate 
cancer treated with molecular radiotherapy. Br. J. Radiol., 2018, 
20170795. 
[3] Oyen, W.J.; de Bono, J.S., Targeted α-Based Treatment of Meta-
static Castration-Resistant Prostate Cancer: Revolutionizing Sys-
temic Radiotherapy?. J Nucl Med, 2016, 57, (12), 1838-1839. 
[4] Oyen, W., Radiopharmaceuticals in the elderly cancer patient: 
practical considerations, with a focus on prostate cancer therapy. 
Eur. J. Cancer, 2017;77, 127-139. 
[5] Rose, T.; Garcia, E.; Bachand, F.; Kim, D.; Petrik, D.; Halperin, R.; 
Crook, J., QOL Comparison of Acute Side Effects From a High 
Dose Rate Vs. Low Dose Rate Prostate Brachytherapy Boost Com-
bined With External Beam Radiotherapy. Brachytherapy, 2015, 14, 
S36. 
[6] Savard, J.; Ivers, H.; Savard, M.H.; Morin, C.M., Cancer treatments 
and their side effects are associated with aggravation of insomnia: 
results of a longitudinal study. Cancer, 2015, 121, (10), 1703-1711. 
[7] De Francesco, I.; Thomas, K.; Tait, D., Pelvic intensity-modulated 
radiotherapy: can we better quantify the late side-effects? Clin. On-
col., 2015, 27, (7), 428. 
[8] Harrabi, S.B.; Adeberg, S.; Welzel, T.; Rieken, S.; Habermehl, D.; 
Debus, J.; Combs, S.E., Long term results after fractionated stereo-
tactic radiotherapy (FSRT) in patients with craniopharyngioma: 
maximal tumor control with minimal side effects. Radiat. Oncol., 
2014, 9, (1), 203. 
[9] West, C.; Azria, D.; Chang-Claude, J.; Davidson, S.; Lambin, P.; 
Rosenstein, B.; De Ruysscher, D.; Talbot, C.; Thierens, H.; Val-
dagni, R., The REQUITE project: validating predictive models and 
biomarkers of radiotherapy toxicity to reduce side-effects and im-
prove quality of life in cancer survivors. Clin. Oncol., 2014, 26, 
(12), 739-742. 
[10] Chung, S.I.; Smart, D.K.; Chung, E.J.; Citrin, D.E. In Increasing 
the Therapeutic Ratio of Radiotherapy, Springer, 2017, 79-102. 
Mechanisms for Radioprotection by Melatonin Current Molecular Pharmacology, 2018, Vol. 11, No. 00    7 
[11] Johnke, R.M.; Sattler, J.A.; Allison, R.R., Radioprotective agents 
for radiation therapy: future trends. Fut. Oncol., 2014, 10, (15), 
2345-2357. 
[12] Prasanna, P.G.; Narayanan, D.; Hallett, K.; Bernhard, E.J.; Ahmed, 
M.M.; Evans, G.; Vikram, B.; Weingarten, M.; Coleman, C.N., 
Radioprotectors and radiomitigators for improving radiation thera-
py: The Small Business Innovation Research (SBIR) gateway for 
accelerating clinical translation. Radiat. Res., 2015, 184, (3), 235-
248. 
[13] Rosen, E.M.; Day, R.; Singh, V.K., New approaches to radiation 
protection. Front. Oncol., 2015, 4, 381. 
[14] Alok, A.; Chaudhury, N., Tetracycline hydrochloride: A potential 
clinical drug for radioprotection. Chemico-biological interactions, 
2016, 245, 90-99. 
[15] Nimesh, H.; Tiwari, V.; Yang, C.; Gundala, S.R.; Chuttani, K.; 
Hazari, P.P.; Mishra, A.K.; Sharma, A.; Lal, J.; Katyal, A., Preclin-
ical evaluation of DMA, a bisbenzimidazole, as radioprotector: 
Toxicity, pharmacokinetics, and biodistribution studies in Balb/c 
mice. Mol. Pharmacol., 2015, 88, (4), 768-778. 
[16] Smith, B.R.; Eastman, C.M.; Njardarson, J.T., Beyond C, H, O, and 
N! Analysis of the Elemental Composition of US FDA Approved 
Drug Architectures: Miniperspective. J. Med. Chem., 2014, 57, 
(23), 9764-9773. 
[17] Gu, J.; Zhu, S.; Li, X.; Wu, H.; Li, Y.; Hua, F., Effect of amifostine 
in head and neck cancer patients treated with radiotherapy: a sys-
tematic review and meta-analysis based on randomized controlled 
trials. PloS One, 2014, 9, (5), e95968. 
[18] Singh, V.K.; Fatanmi, O.O.; Wise, S.Y.; Newman, V.L.; Romaine, 
P.L.; Seed, T.M., The potentiation of the radioprotective efficacy of 
two medical countermeasures, gamma-tocotrienol and amifostine, 
by a combination prophylactic modality. Radiat. Protect. Dos., 
2016, 172, (1-3), 302-310. 
[19] Koukourakis, M.I.; Giatromanolaki, A.; Zois, C.E.; Kalamida, D.; 
Pouliliou, S.; Karagounis, I.V.; Yeh, T.-L.; Abboud, M.I.; Claridge, 
T.D.; Schofield, C.J., Normal tissue radioprotection by amifostine 
via Warburg-type effects. Sci. Rep., 2016, 6, 30986. 
[20] Kamran, M.Z.; Ranjan, A.; Kaur, N.; Sur, S.; Tandon, V., Radio-
protective agents: strategies and translational advances. Med. Res. 
Rev., 2016, 36, (3), 461-493. 
[21] Tan, D.-X.; Manchester, L.C.; Esteban-Zubero, E.; Zhou, Z.; 
Reiter, R.J., Melatonin as a potent and inducible endogenous anti-
oxidant: synthesis and metabolism. Molecules, 2015, 20, (10), 
18886-18906. 
[22] Vriend, J.; Reiter, R.J., Melatonin feedback on clock genes: a theo-
ry involving the proteasome. J. Pineal. Res., 2015, 58, (1), 1-11. 
[23] Tordjman, S.; Chokron, S.; Delorme, R.; Charrier, A.; Bellissant, 
E.; Jaafari, N.; Fougerou, C., Melatonin: pharmacology, functions 
and therapeutic benefits. Curr. Neuropharmacol., 2017, 15, (3), 
434-443. 
[24] Vinther, A.; Claesson, M., The influence of melatonin on the im-
mune system and cancer. Article in Danish]. Ugeskr Laeger, 2015, 
177, V10140568. 
[25] Lacoste, B.; Angeloni, D.; Dominguez‐Lopez, S.; Calderoni, S.; 
Mauro, A.; Fraschini, F.; Descarries, L.; Gobbi, G., Anatomical and 
cellular localization of melatonin MT1 and MT2 receptors in the 
adult rat brain. J. pineal. Res., 2015, 58, (4), 397-417. 
[26] Ren, W.; Liu, G.; Chen, S.; Yin, J.; Wang, J.; Tan, B.; Wu, G.; 
Bazer, F.W.; Peng, Y.; Li, T., Melatonin signaling in T cells: Func-
tions and applications. J. Pineal Res., 2017. 
[27] Hardeland, R., Melatonin-More than just a pineal hormone. Bio-
med. J. Sci. Tech. Res, 2017, 1. 
[28] Liu, R.; Fu, A.; Hoffman, A.E.; Zheng, T.; Zhu, Y., Melatonin 
enhances DNA repair capacity possibly by affecting genes involved 
in DNA damage responsive pathways. BMC Cell Biol., 2013, 14, 1. 
[29] Sliwinski, T.; Rozej, W.; Morawiec-Bajda, A.; Morawiec, Z.; 
Reiter, R.; Blasiak, J., Protective action of melatonin against oxida-
tive DNA damage: chemical inactivation versus base-excision re-
pair. Mutat. Res., 2007, 634, (1-2), 220-227. 
[30] Majidinia, M.; Sadeghpour, A.; Mehrzadi, S.; Reiter, R.J.; Khata-
mi, N.; Yousefi, B., Melatonin: A pleiotropic molecule that modu-
lates DNA damage response and repair pathways. J. Pineal. Res., 
2017, 63, (1). 
[31] Ferreira, S.G.; Peliciari-Garcia, R.A.; Takahashi-Hyodo, S.A.; 
Rodrigues, A.C.; Amaral, F.G.; Berra, C.M.; Bordin, S.; Curi, R.; 
Cipolla-Neto, J., Effects of melatonin on DNA damage induced by 
cyclophosphamide in rats. Braz. J. Med. Biol. Res., 2013, 46, (3), 
278-286. 
[32] Santoro, R.; Marani, M.; Blandino, G.; Muti, P.; Strano, S., Mela-
tonin triggers p53Ser phosphorylation and prevents DNA damage 
accumulation. Oncogene, 2011, 31, 2931. 
[33] Chuffa, L.G.; Fioruci-Fontanelli, B.A.; Mendes, L.O.; Ferreira 
Seiva, F.R.; Martinez, M.; Favaro, W.J.; Domeniconi, R.F.; Pinhei-
ro, P.F.; Delazari Dos Santos, L.; Martinez, F.E., Melatonin attenu-
ates the TLR4-mediated inflammatory response through MyD88- 
and TRIF-dependent signaling pathways in an in vivo model of 
ovarian cancer. BMC Cancer, 2015, 15, 34. 
[34] Nduhirabandi, F.; Lamont, K.; Albertyn, Z.; Opie, L.H.; Lecour, S., 
Role of toll-like receptor 4 in melatonin-induced cardioprotection. 
J. Pineal. Res., 2016, 60, (1), 39-47. 
[35] Hu, Y.; Wang, Z.; Pan, S.; Zhang, H.; Fang, M.; Jiang, H.; Zhang, 
H.; Gao, Z.; Xu, K.; Li, Z.; Xiao, J.; Lin, Z., Melatonin protects 
against blood-brain barrier damage by inhibiting the TLR4/ NF-
kappaB signaling pathway after LPS treatment in neonatal rats. 
Oncotarget, 2017, 8, (19), 31638-31654. 
[36] Esposito, E.; Cuzzocrea, S., Antiinflammatory Activity of Melato-
nin in Central Nervous System. Curr. Neuropharmacol., 2010, 8, 
(3), 228-242. 
[37] Favero, G.; Franceschetti, L.; Bonomini, F.; Rodella, L.F.; Rezzani, 
R., Melatonin as an Anti-Inflammatory Agent Modulating Inflam-
masome Activation. Int. J. Endocrinol., 2017, 2017, 1835195. 
[38] Reiter, R.J.; Calvo, J.R.; Karbownik, M.; Qi, W.; Tan, D.X., Mela-
tonin and its relation to the immune system and inflammation. Ann. 
N Y Acad Sci., 2000, 917, 376-386. 
[39] Reiter, R.J.; Tan, D.X.; Manchester, L.C.; Qi, W., Biochemical 
reactivity of melatonin with reactive oxygen and nitrogen species: a 
review of the evidence. Cell Biochem Biophys, 2001, 34, (2), 237-
256. 
[40] Reiter, R.J.; Acuna-Castroviejo, D.; Tan, D.X.; Burkhardt, S., Free 
radical-mediated molecular damage. Mechanisms for the protective 
actions of melatonin in the central nervous system. Ann. N Y Acad. 
Sci., 2001, 939, 200-215. 
[41] Reiter, R.J.; Tan, D.X.; Gitto, E.; Sainz, R.M.; Mayo, J.C.; Leon, 
J.; Manchester, L.C.; Vijayalaxmi; Kilic, E.; Kilic, U., Pharmaco-
logical utility of melatonin in reducing oxidative cellular and mo-
lecular damage. Pol. J. Pharmacol., 2004, 56, (2), 159-170. 
[42] Yahyapour, R.; Amini, P.; Rezapour, S.; Cheki, M.; Rezaeyan, A.; 
Farhood, B.; Shabeeb, D.; Musa, A.E.; Fallah, H.; Najafi, M., Ra-
diation-induced inflammation and autoimmune diseases. Military 
Medical Res., 2018, 5, (1), 9. 
[43] Vijayalaxmi; Reiter, R.J.; Tan, D.X.; Herman, T.S.; Thomas, C.R., 
Jr., Melatonin as a radioprotective agent: a review. Int. J. Radiat. 
Oncol. Biol. Phys., 2004, 59, (3), 639-653. 
[44] Zetner, D.; Andersen, L.P.; Rosenberg, J., Melatonin as Protection 
Against Radiation Injury: A Systematic Review. Drug Res. 
(Stuttg), 2016, 66, (6), 281-296. 
[45] Das, B.; Bennett, P.V.; Cutter, N.C.; Sutherland, J.C.; Sutherland, 
B.M., Melatonin protects human cells from clustered DNA damag-
es, killing and acquisition of soft agar growth induced by X-rays or 
970 MeV/n Fe ions. Int. J. Radiat. Biol., 2011, 87, (6), 545-555. 
[46] Vijayalaxmi; Reiter, R.J.; Meltz, M.L., Melatonin protects human 
blood lymphocytes from radiation-induced chromosome damage. 
Mutat. Res., 1995, 346, (1), 23-31. 
[47] Vijayalaxmi; Reiter, R.J.; Herman, T.S.; Meltz, M.L., Melatonin 
and radioprotection from genetic damage: in vivo/in vitro studies 
with human volunteers. Mutat. Res., 1996, 371, (3-4), 221-228. 
[48] Vijayalaxmi; Reiter, R.J.; Herman, T.S.; Meltz, M.L., Melatonin 
reduces gamma radiation-induced primary DNA damage in human 
blood lymphocytes. Mutat. Res., 1998, 397, (2), 203-208. 
[49] Manda, K.; Ueno, M.; Anzai, K., AFMK, a melatonin metabolite, 
attenuates X-ray-induced oxidative damage to DNA, proteins and 
lipids in mice. J. Pineal. Res., 2007, 42, (4), 386-393. 
[50] Sener, G.; Jahovic, N.; Tosun, O.; Atasoy, B.M.; Yegen, B.C., 
Melatonin ameliorates ionizing radiation-induced oxidative organ 
damage in rats. Life Sci., 2003, 74, (5), 563-572. 
[51] Koc, M.; Buyukokuroglu, M.E.; Taysi, S., The effect of melatonin 
on peripheral blood cells during total body irradiation in rats. Biol. 
Pharm. Bull, 2002, 25, (5), 656-657. 
[52] Vijayalaxmi; Meltz, M.L.; Reiter, R.J.; Herman, T.S., Melatonin 
and protection from genetic damage in blood and bone marrow: 
whole-body irradiation studies in mice. J. Pineal. Res., 1999, 27, 
(4), 221-225. 
8    Current Molecular Pharmacology, 2018, Vol. 11, No. 00 Amini et al. 
[53] Assayed, M.E.; Abd El-Aty, A.M., Protection of rat chromosomes 
by melatonin against gamma radiation-induced damage. Mutat. 
Res., 2009, 677, (1-2), 14-20. 
[54] Badr, F.M.; El Habit, O.H.; Harraz, M.M., Radioprotective effect 
of melatonin assessed by measuring chromosomal damage in mitot-
ic and meiotic cells. Mutat. Res., 1999, 444, (2), 367-372. 
[55] Manda, K.; Ueno, M.; Anzai, K., Space radiation‐induced inhibi-
tion of neurogenesis in the hippocampal dentate gyrus and memory 
impairment in mice: ameliorative potential of the melatonin metab-
olite, AFMK. J. Pineal. Res., 2008, 45, (4), 430-438. 
[56] Alonso-Gonzalez, C.; Gonzalez, A.; Martinez-Campa, C.; Gomez-
Arozamena, J.; Cos, S., Melatonin sensitizes human breast cancer 
cells to ionizing radiation by downregulating proteins involved in 
double-strand DNA break repair. J. Pineal. Res., 2015, 58, (2), 
189-197. 
[57] Alonso-Gonzalez, C.; Gonzalez, A.; Martinez-Campa, C.; Menen-
dez-Menendez, J.; Gomez-Arozamena, J.; Garcia-Vidal, A.; Cos, 
S., Melatonin enhancement of the radiosensitivity of human breast 
cancer cells is associated with the modulation of proteins involved 
in estrogen biosynthesis. Cancer Lett., 2016, 370, (1), 145-152. 
[58] Griffin, F.; Marignol, L., Therapeutic potential of melatonin for 
breast cancer radiation therapy patients. Int. J. Radiat. Biol., 2018, 
94, (5), 472-477. 
[59] Manchester, L.C.; Coto‐Montes, A.; Boga, J.A.; Andersen, L.P.H.; 
Zhou, Z.; Galano, A.; Vriend, J.; Tan, D.X.; Reiter, R.J., Melato-
nin: an ancient molecule that makes oxygen metabolically tolera-
ble. J. Pineal. Res., 2015, 59, (4), 403-419. 
[60] Zhang, H.M.; Zhang, Y., Melatonin: a well‐documented antioxi-
dant with conditional pro‐oxidant actions. J. Pineal. Res., 2014, 57, 
(2), 131-146. 
[61] Ogawa, Y.; Sekine-Suzuki, E.; Nakanishi, I.; Matsumoto, K.-i., 
LET dependent hydroxyl radical generation in water by heavy-ion 
beam irradiation. Free Radic. Biol. Med., 2017, 112, 63. 
[62] Lafargue, A.; Degorre, C.; Corre, I.; Alves-Guerra, M.-C.; Gaugler, 
M.-H.; Vallette, F.; Pecqueur, C.; Paris, F., Ionizing radiation in-
duces long-term senescence in endothelial cells through mitochon-
drial respiratory complex II dysfunction and superoxide generation. 
Free Radic. Biol. Med., 2017, 108, 750-759. 
[63] Marklund, S.L.; Westman, N.G.; Lundgren, E.; Roos, G., Copper-
and zinc-containing superoxide dismutase, manganese-containing 
superoxide dismutase, catalase, and glutathione peroxidase in nor-
mal and neoplastic human cell lines and normal human tissues. 
Cancer Res., 1982, 42, (5), 1955-1961. 
[64] Simon, H.-U.; Haj-Yehia, A.; Levi-Schaffer, F., Role of reactive 
oxygen species (ROS) in apoptosis induction. Apoptosis, 2000, 5, 
(5), 415-418. 
[65] Leach, J.K.; Van Tuyle, G.; Lin, P.-S.; Schmidt-Ullrich, R.; Mik-
kelsen, R.B., Ionizing radiation-induced, mitochondria-dependent 
generation of reactive oxygen/nitrogen. Cancer Res., 2001, 61, 
(10), 3894-3901. 
[66] Spitz, D.R.; Azzam, E.I.; Li, J.J.; Gius, D., Metabolic oxida-
tion/reduction reactions and cellular responses to ionizing radia-
tion: a unifying concept in stress response biology. Cancer Metas-
tasis Rev., 2004, 23, (3-4), 311-322. 
[67] Jaiswal, M.; LaRusso, N.F.; Nishioka, N.; Nakabeppu, Y.; Gores, 
G.J., Human Ogg1, a protein involved in the repair of 8-
oxoguanine, is inhibited by nitric oxide. Cancer Res., 2001, 61, 
(17), 6388-6393. 
[68] Chien, Y.-H.; Bau, D.-T.; Jan, K.-Y., Nitric oxide inhibits DNA-
adduct excision in nucleotide excision repair. Free Radic. Biol. 
Med., 2004, 36, (8), 1011-1017. 
[69] Reiter, R.J.; Mayo, J.C.; Tan, D.X.; Sainz, R.M.; Alatorre‐Jimenez, 
M.; Qin, L., Melatonin as an antioxidant: under promises but over 
delivers. J. Pineal. Res., 2016, 61, (3), 253-278. 
[70] Karbownik, M.; Reiter, R.J., Antioxidative effects of melatonin in 
protection against cellular damage caused by ionizing radiation. 
Proc. Soc. Exp. Biol. Med., 2000, 225, (1), 9-22. 
[71] Marta, B.; Szafrańska, K.; Posmyk, M.M., Exogenous melatonin 
improves antioxidant defense in cucumber seeds (Cucumis sativus 
L.) germinated under chilling stress. Front. Plant Sci., 2016, 7, 575. 
[72] Gurer-Orhan, H.; Suzen, S., Melatonin, its metabolites and its 
synthetic analogs as multi-faceted compounds: antioxidant, prooxi-
dant and inhibitor of bioactivation reactions. Curr. Med. Chem., 
2015, 22, (4), 490-499. 
[73] Koc, M.; Taysi, S.; Emin Buyukokuroglu, M.; Bakan, N., The 
Effect of Melatonin against Oxidative Damage during Total-Body 
Irradiation in Rats. Radiat. Res., 2003, 160, (2), 251-255. 
[74] Erol, F.S.; Topsakal, C.; Ozveren, M.F.; Kaplan, M.; Ilhan, N.; 
Ozercan, I.H.; Yildiz, O.G., Protective effects of melatonin and vit-
amin E in brain damage due to gamma radiation. Neurosurg. Rev., 
2004, 27, (1), 65-69. 
[75] Bhatia, A.L.; Manda, K., Study on pre-treatment of melatonin 
against radiation-induced oxidative stress in mice. Env. Toxicol. 
Pharmacol., 2004, 18, (1), 13-20. 
[76] Karslioglu, I.; Ertekin, M.V.; Taysi, S.; Kocer, I.; Sezen, O.; 
Gepdiremen, A.; Koc, M.; Bakan, N., Radioprotective effects of 
melatonin on radiation-induced cataract. J. Radiat. Res., 2005, 46, 
(2), 277-282. 
[77] Kailash, M.; Megumi, U.; Kazunori, A., Space radiation‐induced 
inhibition of neurogenesis in the hippocampal dentate gyrus and 
memory impairment in mice: ameliorative potential of the melato-
nin metabolite, AFMK. J. Pineal. Res., 2008, 45, (4), 430-438. 
[78] Ündeğer, Ü.; Giray, B.; Zorlu, A.F.; Öge, K.; Baçaran, N., Protec-
tive effects of melatonin on the ionizing radiation induced DNA 
damage in the rat brain. Exp. Toxicol. Pathol., 2004, 55, (5), 379-
384. 
[79] Şener, G.; Atasoy, B.M.; Ersoy, Y.; Arbak, S.; Şengöz, M.; Yeğen, 
B.Ç., Melatonin protects against ionizing radiation‐induced oxida-
tive damage in corpus cavernosum and urinary bladder in rats. J. 
Pineal. Res., 2004, 37, (4), 241-246. 
[80] Yildirim, O.; Comoğlu, S.; Yardimci, S.; Akmansu, M.; Bozkurt, 
G.; Sürücü, S., Preserving effects of melatonin on the levels of glu-
tathione and malondialdehyde in rats exposed to irradiation. Gen-
eral physiology and biophysics, 2008, 27, (1), 32-37. 
[81] Sharma, S.; Haldar, C., Melatonin prevents X-ray irradiation in-
duced oxidative damagein peripheral blood and spleen of the sea-
sonally breeding rodent, Funambulus pennanti during reproductive-
ly active phase. Internat j radiat biol, 2006, 82, (6), 411-419. 
[82] Sharma, S.; Haldar, C.; Chaube, S.K., Effect of exogenous melato-
nin on X-ray induced cellular toxicity in lymphatic tissue of Indian 
tropical male squirrel, Funambulus pennanti. International journal 
of radiation biology, 2008, 84, (5), 363-374. 
[83] Najafi, M.; Shirazi, A.; Motevaseli, E.; Geraily, G.; Norouzi, F.; 
Heidari, M.; Rezapoor, S., The melatonin immunomodulatory ac-
tions in radiotherapy. Biophysical Reviews, 2017, 9, (2), 139-148. 
[84] Miller, E.; Morel, A.; Saso, L.; Saluk, J., Melatonin redox activity. 
Its potential clinical applications in neurodegenerative disorders. 
Current topics in medicinal chemistry, 2015, 15, (2), 163-169. 
[85] Guo, Y.; Sun, J.; Li, T.; Zhang, Q.; Bu, S.; Wang, Q.; Lai, D., 
Melatonin ameliorates restraint stress-induced oxidative stress and 
apoptosis in testicular cells via NF-κB/iNOS and Nrf2/ HO-1 sig-
naling pathway. Sci Rep, 2017, 7, 9599. 
[86] Jung, K.H.; Hong, S.W.; Zheng, H.M.; Lee, H.S.; Lee, H.; Lee, 
D.H.; Lee, S.Y.; Hong, S.S., Melatonin ameliorates cerulein-
induced pancreatitis by the modulation of nuclear erythroid 2-
related factor 2 and nuclear factor-kappaB in rats. J Pineal Res, 
2010, 48, (3), 239-250. 
[87] Janjetovic, Z.; Jarrett, S.G.; Lee, E.F.; Duprey, C.; Reiter, R.J.; 
Slominski, A.T., Melatonin and its metabolites protect human mel-
anocytes against UVB-induced damage: Involvement of NRF2-
mediated pathways. Sci Rep, 2017, 7, (1), 1274. 
[88] Tripathi, D.N.; Jena, G.B., Effect of melatonin on the expression of 
Nrf2 and NF-kappaB during cyclophosphamide-induced urinary 
bladder injury in rat. J Pineal Res, 2010, 48, (4), 324-331. 
[89] Negi, G.; Kumar, A.; Sharma, S.S., Melatonin modulates neuroin-
flammation and oxidative stress in experimental diabetic neuropa-
thy: effects on NF-kappaB and Nrf2 cascades. J Pineal Res, 2011, 
50, (2), 124-131. 
[90] Yahyapour, R.; Motevaseli, E.; Rezaeyan, A.; Abdollahi, H.; Far-
hood, B.; Cheki, M.; Rezapoor, S.; Shabeeb, D.; Musa, A.E.; 
Najafi, M.; Villa, V., Reduction-oxidation (redox) system in radia-
tion-induced normal tissue injury: molecular mechanisms and im-
plications in radiation therapeutics. Clin Transl Oncol, 2018. doi: 
10.1007/s12094-017-1828-6. [Epub ahead of print] 
[91] Szumiel, I., Ionizing radiation-induced oxidative stress, epigenetic 
changes and genomic instability: the pivotal role of mitochondria. 
International journal of radiation biology, 2015, 91, (1), 1-12. 
[92] Cheki, M.; Yahyapour, R.; Farhood, B.; Rezaeyan, A.; Shabeeb, 
D.; Amini, P.; Rezapoor, S.; Najafi, M., COX-2 in Radiotherapy; a 
Mechanisms for Radioprotection by Melatonin Current Molecular Pharmacology, 2018, Vol. 11, No. 00    9 
potential target for radioprotection and radiosensitization. Curr Mol 
Pharmacol, 2018. 11(3): 173-183. 
[93] Yahyapour, R.; Amini, P.; Rezapoor, S.; Rezaeyan, A.; Farhood, 
B.; Cheki, M.; Fallah, H.; Najafi, M., Targeting of Inflammation 
for Radiation Protection and Mitigation. Curr Mol Pharmacol, 
2018. 11(3): 203-210. 
[94] Najafi, M.; Motevaseli, E.; Shirazi, A.; Geraily, G.; Rezaeyan, A.; 
Norouzi, F.; Rezapoor, S.; Abdollahi, H., Mechanisms of inflam-
matory responses to radiation and normal tissues toxicity: clinical 
implications. Int J Radiat Biol, 2018, 94, (4), 335-356. 
[95] Wang, Y.; Liu, L.; Pazhanisamy, S.K.; Li, H.; Meng, A.; Zhou, D., 
Total body irradiation causes residual bone marrow injury by in-
duction of persistent oxidative stress in murine hematopoietic stem 
cells. Free Radic Biol Med, 2010, 48, (2), 348-356. 
[96] Pazhanisamy, S.K.; Li, H.; Wang, Y.; Batinic-Haberle, I.; Zhou, 
D., NADPH oxidase inhibition attenuates total body irradiation-
induced haematopoietic genomic instability. Mutagenesis, 2011, 
26, (3), 431-435. 
[97] Mao, X.W.; Nishiyama, N.C.; Campbell-Beachler, M.; Gifford, P.; 
Haynes, K.E.; Gridley, D.S.; Pecaut, M.J., Role of NADPH Oxi-
dase as a Mediator of Oxidative Damage in Low-Dose Irradiated 
and Hindlimb-Unloaded Mice. Radiat Res, 2017, 188, (4), 392-399. 
[98] Sakai, Y.; Yamamori, T.; Yoshikawa, Y.; Bo, T.; Suzuki, M.; 
Yamamoto, K.; Ago, T.; Inanami, O., NADPH oxidase 4 mediates 
ROS production in radiation-induced senescent cells and promotes 
migration of inflammatory cells. Free Radic Res, 2018, 52, (1), 92-
102. 
[99] Weyemi, U.; Redon, C.E.; Aziz, T.; Choudhuri, R.; Maeda, D.; 
Parekh, P.R.; Bonner, M.Y.; Arbiser, J.L.; Bonner, W.M., Inactiva-
tion of NADPH oxidases NOX4 and NOX5 protects human prima-
ry fibroblasts from ionizing radiation-induced DNA damage. Radi-
at Res, 2015, 183, (3), 262-270. 
[100] Collins-Underwood, J.R.; Zhao, W.; Sharpe, J.G.; Robbins, M.E., 
NADPH oxidase mediates radiation-induced oxidative stress in rat 
brain microvascular endothelial cells. Free radical biology & med-
icine, 2008, 45, (6), 929-938. 
[101] Cagin, Y.F.; Parlakpinar, H.; Polat, A.; Vardi, N.; Atayan, Y.; 
Erdogan, M.A.; Ekici, K.; Yildiz, A.; Sarihan, M.E.; Aladag, H., 
The protective effects of apocynin on ionizing radiation-induced in-
testinal damage in rats. Drug Dev Ind Pharm, 2016, 42, (2), 317-
324. 
[102] Wang, Y.; Liu, Q.; Zhao, W.; Zhou, X.; Miao, G.; Sun, C.; Zhang, 
H., NADPH Oxidase Activation Contributes to Heavy Ion Irradia-
tion–Induced Cell Death. Dose-Response, 2017, 15, (1), 
1559325817699697. 
[103] Khayyal, M.T.; El-Ghazaly, M.A.; El-Hazek, R.M.; Nada, A.S., 
The effects of celecoxib, a COX-2 selective inhibitor, on acute in-
flammation induced in irradiated rats. Inflammopharmacology, 
2009, 17, (5), 255-266. 
[104] Pinheiro, R.M.; Calixto, J.B., Effect of the selective COX-2 inhibi-
tors, celecoxib and rofecoxib in rat acute models of inflammation. 
Inflamm Res, 2002, 51, (12), 603-610. 
[105] Malaviya, R.; Gow, A.J.; Francis, M.; Abramova, E.V.; Laskin, 
J.D.; Laskin, D.L., Radiation-Induced Lung Injury and Inflamma-
tion in Mice: Role of Inducible Nitric Oxide Synthase and Surfac-
tant Protein D. Toxicological Sciences, 2015, 144, (1), 27-38. 
[106] Hosseinimehr, S.J.; Fathi, M.; Ghasemi, A.; Shiadeh, S.N.R.; Pour-
fallah, T.A., Celecoxib mitigates genotoxicity induced by ionizing 
radiation in human blood lymphocytes. Research in Pharmaceuti-
cal Sciences, 2017, 12, (1), 82-87. 
[107] Fardid, R.; Najafi, M.; Salajegheh, A.; Kazemi, E.; Rezaeyan, A., 
Radiation-induced non-targeted effect in vivo: Evaluation of cy-
clooygenase-2 and endothelin-1 gene expression in rat heart tis-
sues. J Cancer Res Ther, 2017, 13, (1), 51-55. 
[108] R Ramis, M.; Esteban, S.; Miralles, A.; Tan, D.-X.; J Reiter, R., 
Protective effects of melatonin and mitochondria-targeted antioxi-
dants against oxidative stress: A review. Cur med chem, 2015, 22, 
(22), 2690-2711. 
[109] Zhou, J.; Zhang, S.; Zhao, X.; Wei, T., Melatonin impairs NADPH 
oxidase assembly and decreases superoxide anion production in 
microglia exposed to amyloid-beta1-42. J Pineal Res, 2008, 45, (2), 
157-165. 
[110] Tain, Y.L.; Chen, C.C.; Lee, C.T.; Kao, Y.H.; Sheen, J.M.; Yu, 
H.R.; Huang, L.T., Melatonin regulates L-arginine transport and 
NADPH oxidase in young rats with bile duct ligation: role of pro-
tein kinase C. Pediatr Res, 2013, 73, (4 Pt 1), 395-401. 
[111] Li, D.; Tian, Z.; Tang, W.; Zhang, J.; Lu, L.; Sun, Z.; Zhou, Z.; 
Fan, F., The Protective Effects of 5-Methoxytryptamine-α-lipoic 
Acid on Ionizing Radiation-Induced Hematopoietic Injury. Interna-
tional Journal of Molecular Sciences, 2016, 17, (6), 935. 
[112] Fardid, R.; Salajegheh, A.; Mosleh-Shirazi, M.A.; Sharifzadeh, S.; 
Okhovat, M.A.; Najafi, M.; Rezaeyan, A.; Abaszadeh, A., Melato-
nin Ameliorates The Production of COX-2, iNOS, and The For-
mation of 8-OHdG in Non-Targeted Lung Tissue after Pelvic Irra-
diation. Cell J, 2017, 19, (2), 324-331. 
[113] Ghobadi, A.; Shirazi, A.; Najafi, M.; Kahkesh, M.H.; Rezapoor, S., 
Melatonin ameliorates radiation-induced oxidative stress at targeted 
and nontargeted lung tissue. J Med Phys, 2017, 42, (4), 241. 
[114] Shirazi, A.; Hadadi, G.H.; Ghazi, K.M.; Abou, A.F.; Mahdavi, 
S.R.; Eshraghian, M., Evaluation of melatonin for prevention of ra-
diation myelopathy in irradiated cervical spinal cord. 2009. 
[115] Haddadi, G.; Shirazi, A.; Sepehrizadeh, Z.; Mahdavi, S.R.; Had-
dadi, M., Radioprotective effect of melatonin on the cervical spinal 
cord in irradiated rats. Cell J (Yakhteh), 2013, 14, (4), 246. 
[116] Aghazadeh, S.; Azarnia, M.; Shirazi, A.; Mahdavi, S.R.; Zangii, 
B.M., Melatonin as a protective agent in spinal cord damage after 
gamma irradiation. Report Pract Oncol Radioth, 2007, 12, (2), 95-
99. 
[117] Ortiz, F.; Acuna-Castroviejo, D.; Doerrier, C.; Dayoub, J.C.; 
Lopez, L.C.; Venegas, C.; Garcia, J.A.; Lopez, A.; Volt, H.; Luna-
Sanchez, M.; Escames, G., Melatonin blunts the mitochondri-
al/NLRP3 connection and protects against radiation-induced oral 
mucositis. J Pineal Res, 2015, 58, (1), 34-49. 
[118] Leach, J.K.; Van Tuyle, G.; Lin, P.S.; Schmidt-Ullrich, R.; Mikkel-
sen, R.B., Ionizing radiation-induced, mitochondria-dependent 
generation of reactive oxygen/nitrogen. Cancer Res, 2001, 61, (10), 
3894-3901. 
[119] Strom, E.; Sathe, S.; Komarov, P.G.; Chernova, O.B.; Pavlovska, 
I.; Shyshynova, I.; Bosykh, D.A.; Burdelya, L.G.; Macklis, R.M.; 
Skaliter, R.; Komarova, E.A.; Gudkov, A.V., Small-molecule in-
hibitor of p53 binding to mitochondria protects mice from gamma 
radiation. Nat Chem Biol, 2006, 2, (9), 474-479. 
[120] Fischer, T.W.; Zmijewski, M.A.; Wortsman, J.; Slominski, A., 
Melatonin maintains mitochondrial membrane potential and attenu-
ates activation of initiator (casp-9) and effector caspases (casp-
3/casp-7) and PARP in UVR-exposed HaCaT keratinocytes. J Pin-
eal Res, 2008, 44, (4), 397-407. 
[121] Mohseni, M.; Mihandoost, E.; Shirazi, A.; Sepehrizadeh, Z.; 
Bazzaz, J.T.; Ghazi-khansari, M., Melatonin may play a role in 
modulation of bax and bcl-2 expression levels to protect rat periph-
eral blood lymphocytes from gamma irradiation-induced apoptosis. 
Mutat Res, 2012, 738-739, 19-27. 
[122] Kawanishi, S.; Ohnishi, S.; Ma, N.; Hiraku, Y.; Oikawa, S.; Mura-
ta, M., Nitrative and oxidative DNA damage in infection-related 
carcinogenesis in relation to cancer stem cells. Genes and environ-
ment, 2016, 38, (1), 26. 
[123] Basudhar, D.; Somasundaram, V.; de Oliveira, G.A.; Kesarwala, 
A.; Heinecke, J.L.; Cheng, R.Y.; Glynn, S.A.; Ambs, S.; Wink, 
D.A.; Ridnour, L.A., Nitric oxide synthase-2-derived nitric oxide 
drives multiple pathways of breast cancer progression. Antioxidants 
& redox signaling, 2017, 26, (18), 1044-1058. 
[124] Vaccaro, M.; Irrera, N.; Cutroneo, G.; Rizzo, G.; Vaccaro, F.; Ana-
stasi, G.P.; Borgia, F.; Cannavò, S.P.; Altavilla, D.; Squadrito, F., 
Differential Expression of Nitric Oxide Synthase Isoforms nNOS 
and iNOS in Patients with Non-Segmental Generalized Vitiligo. In-
ternational journal of molecular sciences, 2017, 18, (12), 2533. 
[125] Zhou, J.; Cheng, G.; Pang, H.; Liu, Q.; Liu, Y., The effect of 131I-
induced hypothyroidism on the levels of nitric oxide (NO), inter-
leukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), total nitric 
oxide synthase (NOS) activity, and expression of NOS isoforms in 
rats. Bosnian journal of basic medical sciences, 2018. 
[126] Nagane, M.; Yasui, H.; Sakai, Y.; Yamamori, T.; Niwa, K.; Hatto-
ri, Y.; Kondo, T.; Inanami, O., Activation of eNOS in endothelial 
cells exposed to ionizing radiation involves components of the 
DNA damage response pathway. Biochem Biophys Res Commun, 
2015, 456, (1), 541-546. 
[127] Zhang, S.; Li, J.; Li, Y.; Liu, Y.; Guo, H.; Xu, X., Nitric Oxide 
Synthase Activity Correlates with OGG1 in Ozone-Induced Lung 
Injury Animal Models. Frontiers in Physiology, 2017, 8, 249. 
[128] Jaiswal, M.; LaRusso, N.F.; Nishioka, N.; Nakabeppu, Y.; Gores, 
G.J., Human Ogg1, a protein involved in the repair of 8-
10    Current Molecular Pharmacology, 2018, Vol. 11, No. 00 Amini et al. 
oxoguanine, is inhibited by nitric oxide. Cancer Res, 2001, 61, 
(17), 6388-6393. 
[129] Chevillard, S.; Radicella, J.P.; Levalois, C.; Lebeau, J.; Poupon, 
M.F.; Oudard, S.; Dutrillaux, B.; Boiteux, S., Mutations in OGG1, 
a gene involved in the repair of oxidative DNA damage, are found 
in human lung and kidney tumours. Oncogene, 1998, 16, (23), 
3083-3086. 
[130] Mahjabeen, I.; Ali, K.; Zhou, X.; Kayani, M.A., Deregulation of 
base excision repair gene expression and enhanced proliferation in 
head and neck squamous cell carcinoma. Tumour Biol, 2014, 35, 
(6), 5971-5983. 
[131] Mahjabeen, I.; Chen, Z.; Zhou, X.; Kayani, M.A., Decreased 
mRNA expression levels of base excision repair (BER) pathway 
genes is associated with enhanced Ki-67 expression in HNSCC. 
Med Oncol, 2012, 29, (5), 3620-3625. 
[132] Kumar, A.; Pant, M.C.; Singh, H.S.; Khandelwal, S., Reduced 
expression of DNA repair genes (XRCC1, XPD, and OGG1) in 
squamous cell carcinoma of head and neck in North India. Tumour 
Biol, 2012, 33, (1), 111-119. 
[133] Galano, A.; Tan, D.-X.; Reiter, R.J., Melatonin: A Versatile Protec-
tor against Oxidative DNA Damage. Molecules, 2018, 23, (3), 530. 
[134] Majidinia, M.; Sadeghpour, A.; Mehrzadi, S.; Reiter, R.J.; Khata-
mi, N.; Yousefi, B., Melatonin: A pleiotropic molecule that modu-
lates DNA damage response and repair pathways. Journal of pineal 
research, 2017. 
[135] Rezapoor, S.; Shirazi, A.; Abbasi, S.; Bazzaz, J.T.; Izadi, P.; Re-
zaeejam, H.; Valizadeh, M.; Soleimani-Mohammadi, F.; Najafi, 
M., Modulation of radiation-induced base excision repair pathway 
gene expression by melatonin. Journal of Medical Physics, 2017, 
42, (4), 245-250. 
[136] Karbownik, M.; Reiter, R.J.; Qi, W.; Garcia, J.J.; Tan, D.X.; Man-
chester, L.C.; Vijayalaxmi, Protective effects of melatonin against 
oxidation of guanine bases in DNA and decreased microsomal 
membrane fluidity in rat liver induced by whole body ionizing ra-
diation. Mol Cell Biochem, 2000, 211, (1-2), 137-144. 
[137] Valizadeh, M.; Shirazi, A.; Izadi, P.; Tavakkoly Bazzaz, J.; Re-
zaeejam, H., Expression Levels of Two DNA Repair-related Genes 
under 8 Gy Ionizing Radiation and 100 Mg/Kg Melatonin Delivery 
In Rat Peripheral Blood. J Biomed Phys Eng, 2017, 7, (1), 27-36. 
[138] Farhood, B.; Goradel, N.H.; Mortezaee, K.; Khanlarkhani, N.; 
Salehi, E.; Nashtaei, M.S.; Shabeeb, D.; Musa, A.E.; Fallah, H.; 
Najafi, M., Intercellular communications-redox interactions in ra-
diation toxicity; potential targets for radiation mitigation. J Cell 
Commun Signal. 2018. doi: 10.1007/s12079-018-0473-3. [Epub 
ahead of print] 
[139] Yahyapour, R.; Motevaseli, E.; Rezaeyan, A.; Abdollahi, H.; Far-
hood, B.; Cheki, M.; Najafi, M.; Villa, V., Mechanisms of Radia-
tion Bystander and Non-Targeted Effects: Implications to Radia-
tion Carcinogenesis and Radiotherapy. Curr Radiopharm, 2018, 
11, (1), 34-45. 
[140] Najafi, M.; Shirazi, A.; Motevaseli, E.; Rezaeyan, A.H.; Sala-
jegheh, A.; Rezapoor, S., Melatonin as an anti-inflammatory agent 
in radiotherapy. Inflammopharmacology, 2017, 25, (4), 403-413. 
[141] Xu, Y.; Chen, Y.; Liu, H.; Lei, X.; Guo, J.; Cao, K.; Liu, C.; Li, B.; 
Cai, J.; Ju, J., Heat-killed salmonella typhimurium (HKST) protects 
mice against radiation in TLR4-dependent manner. Oncotarget, 
2017, 8, (40), 67082. 
[142] Ho, M.-F.; Ingle, J.N.; Bongartz, T.; Kalari, K.R.; Goss, P.E.; 
Shepherd, L.E.; Mushiroda, T.; Kubo, M.; Wang, L.; Weinshil-
boum, R.M., TCL1A SNPs and estrogen-mediated toll-like recep-
tor-MYD88-dependent NF-κB activation: SNP and SERM-
dependent modification of inflammation and immune response. 
Molecular Pharmacology, 2017, mol. 117.108340. 
[143] Taniguchi, K.; Karin, M., NF-κB, inflammation, immunity and 
cancer: coming of age. Nature Reviews Immunology, 2018. 
[144] Wu, Q.; Allouch, A.; Martins, I.; Modjtahedi, N.; Deutsch, E.; 
Perfettini, J.-L., Macrophage biology plays a central role during 
ionizing radiation-elicited tumor response. Biomedical Journal, 
2017, 40, (4), 200-211. 
[145] Hu, Z.P.; Fang, X.L.; Fang, N.; Wang, X.B.; Qian, H.Y.; Cao, Z.; 
Cheng, Y.; Wang, B.N.; Wang, Y., Melatonin ameliorates vascular 
endothelial dysfunction, inflammation, and atherosclerosis by sup-
pressing the TLR4/NF-kappaB system in high-fat-fed rabbits. J 
Pineal Res, 2013, 55, (4), 388-398. 
[146] Mohan, N.; Sadeghi, K.; Reiter, R.J.; Meltz, M.L., The neurohor-
mone melatonin inhibits cytokine, mitogen and ionizing radiation 
induced NF-kappa B. Biochemistry and molecular biology interna-
tional, 1995, 37, (6), 1063-1070. 
[147] García, J.A.; Volt, H.; Venegas, C.; Doerrier, C.; Escames, G.; 
López, L.C.; Acuña-Castroviejo, D., Disruption of the NF-
κB/NLRP3 connection by melatonin requires retinoid-related or-
phan receptor-α and blocks the septic response in mice. FASEB J, 
2015, 29, (9), 3863-3875. 
[148] Yahyapour, R.; Shabeeb, D.; Cheki, M.; Musa, A.E.; Farhood, B.; 
Rezaeyan, A.; Amini, P.; Fallah, H.; Najafi, M., Radiation protec-
tion and mitigation by natural antioxidants and flavonoids; implica-
tions to radiotherapy and radiation disasters. Curr Mol Pharmacol, 
2018. doi: 10.2174/1874467211666180619125653. [Epub ahead of 
print] 
[149] Serin, M.; Gulbas, H.; Gurses, I.; Erkal, H.S.; Yucel, N., The histo-
pathological evaluation of the effectiveness of melatonin as a pro-
tectant against acute lung injury induced by radiation therapy in a 
rat model. Int J Radiat Biol, 2007, 83, (3), 187-193. 
[150] Gurses, I.; Ozeren, M.; Serin, M.; Yucel, N.; Erkal, H.S., Histo-
pathological evaluation of melatonin as a protective agent in heart 
injury induced by radiation in a rat model. Pathol Res Pract, 2014, 
210, (12), 863-871. 
[151] Jang, S.S.; Kim, H.G.; Lee, J.S.; Han, J.M.; Park, H.J.; Huh, G.J.; 
Son, C.G., Melatonin reduces X-ray radiation-induced lung injury 
in mice by modulating oxidative stress and cytokine expression. Int 
J Radiat Biol, 2013, 89, (2), 97-105. 
[152] Fernández-Gil, B.; Moneim, A.E.A.; Ortiz, F.; Shen, Y.-Q.; Soto-
Mercado, V.; Mendivil-Perez, M.; Guerra-Librero, A.; Acuña-
Castroviejo, D.; Molina-Navarro, M.M.; García-Verdugo, J.M.; 
Sayed, R.K.A.; Florido, J.; Luna, J.D.; López, L.C.; Escames, G., 
Melatonin protects rats from radiotherapy-induced small intestine 
toxicity. PLoS ONE, 2017, 12, (4), e0174474. 
[153] Ben-David, M.A.; Elkayam, R.; Gelernter, I.; Pfeffer, R.M., Mela-
tonin for Prevention of Breast Radiation Dermatitis: A Phase II, 
Prospective, Double-Blind Randomized Trial. Isr Med Assoc J, 
2016, 18, (3-4), 188-192. 
[154] Yahyapour, R.; Salajegheh, A.; Safari, A.; Abbasi, S.; Amini, P.; 
Rezaeyan, A.; Amraee, A.; Najafi, M., Radiation-induced Non-
targeted Effect and Carcinogenesis; Implications in Clinical Radio-
therapy. J Biomed Phys Eng, 2018. DOI: 
https://doi.org/10.22086/jbpe.v0i0.713 
[155] Najafi, M.; Fardid, R.; Takhshid, M.A.; Mosleh-Shirazi, M.A.; 
Rezaeyan, A.H.; Salajegheh, A., Radiation-Induced Oxidative 
Stress at Out-of-Field Lung Tissues after Pelvis Irradiation in Rats. 
Cell J, 2016, 18, (3), 340-345. 
[156] Khan, M.A.; Van Dyk, J.; Yeung, I.W.; Hill, R.P., Partial volume 
rat lung irradiation; assessment of early DNA damage in different 
lung regions and effect of radical scavengers. Radiother Oncol, 
2003, 66, (1), 95-102. 
[157] Moiseenko, V.V.; Battista, J.J.; Hill, R.P.; Travis, E.L.; Van Dyk, 
J., In-field and out-of-field effects in partial volume lung irradiation 
in rodents: possible correlation between early dna damage and 
functional endpoints. Int J Radiat Oncol Biol Phys, 2000, 48, (5), 
1539-1548. 
[158] Calveley, V.L.; Khan, M.A.; Yeung, I.W.; Vandyk, J.; Hill, R.P., 
Partial volume rat lung irradiation: temporal fluctuations of in-field 
and out-of-field DNA damage and inflammatory cytokines follow-
ing irradiation. Int J Radiat Biol, 2005, 81, (12), 887-899. 
[159] Marozik, P.; Mothersill, C.; Seymour, C.B.; Mosse, I.; Melnov, S., 
Bystander effects induced by serum from survivors of the Cherno-
byl accident. Exp Hematol, 2007, 35, (4 Suppl 1), 55-63. 
 
DISCLAIMER: The above article has been published in Epub (ahead of print) on the basis of the materials provided by the author. The Editorial Department 
reserves the right to make minor modifications for further improvement of the manuscript. 
PMID: ???????????????????????? 
